Point72 (DIFC)’s 10x Genomics TXG Stock Holding History

Point72 (DIFC)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,121	Closed	-$492K	–	1911
2024 Q1	$492K	Buy	+13,121	New	+$576K	0.02%	749

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Point72 (DIFC)'s TXG Position: Q2 2024 in Review

Point72 (DIFC) sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 13,121 shares — an estimated $492K sold.

Point72 (DIFC) first reported a position in TXG in Q1 2024 and held it in 1 quarter. The position peaked at $492K in Q1 2024. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

Point72 (DIFC) reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
Point72 (DIFC) sold 13,121 10x Genomics shares in Q2 2024, an estimated $492K.
Point72 (DIFC) first reported a position in 10x Genomics in Q1 2024 and held it in 1 quarter.
Point72 (DIFC)'s 10x Genomics position peaked at $492K in Q1 2024.
261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Point72 (DIFC)'s 13F filing for Q2 2024, filed 14 Aug 2024.